Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations

NCT00925301 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT00925301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00925301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations
Lead sponsor
Amicus Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
October 23, 2009
Completion date
January 29, 2014
Enrollment
67 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease